Hui-Kuan Lin, MD, PhD, joined Duke Pathology in 2023, assuming the role of professor and director of Prostate Cancer Research.
Lin is at the forefront of prostate cancer research, focusing on castration-resistant prostate cancer (CRPC). His work involves dissecting metabolic pathways that drive lineage plasticity, a crucial part of CRPC’s adaptability. Additionally, Lin is dedicated to unraveling the mechanisms behind immunotherapy resistance in CRPC.
In his pursuit of innovative treatments, Lin is developing novel agents such as specific gene inhibitors and tumor degrading technology to specifically target and overcome challenges posed by CRPC.
Lin’s groundbreaking contributions to prostate cancer research have garnered widespread recognition, as reflected in a myriad of prestigious awards and nominations.
In addition to the accolades below, Lin has published more than 120 peer-reviewed articles that detail his and his colleagues’ findings, as well as actively contributing to the academic community by serving on grant review panels, editorial boards, and as a reviewer to several high-impact journals like Nature, Science, and Cancer Cell.
Further, Lin collaborates closely with other researchers, fostering partnerships within Duke University and the University of Texas San Antonio. “The faculty members at the Department of Pathology have major strengths and expertise in prostate cancer research,” notes Lin. His excitement resonates as he anticipates significant discoveries on the horizon within the department.
Notable Honors:
- Research Trust Scholar Award and Faculty Scholar Award from MD Anderson Cancer Center
- Young Investigator Award from the Society of Chinese Bioscientists in America
- New Investigator Award from the Department of Defense
- Fellow of the American Association for the Advancement of Science